The stock quoted a 52-week high price of Rs 3040.0 and low of Rs 2232.0.
As of 12:09PM (IST), the counter saw total traded volume of 6,337 shares with a traded value of Rs 1.73 crore, according to NSE.
The stock had closed at Rs 2717.15 in the previous session.
The scrip has advanced 9.08 per cent in the past one month till date, while the benchmark BSE Sensex has gained 6.68 per cent during the same period.
According to exchange data, the stock traded at a price-to-earnings (P/E) multiple of 36.99 while price-to-book ratio stood at 6.92. A higher P/E ratio shows that investors are willing to pay a higher price for per rupee earnings given by the stock because of better future growth expectations. The price-to-book value indicates the inherent value of a company and it reflects the price investors are ready to pay even for no growth in a business.
The stock belongs to the Pharma – Indian industry.
Promoter/FII Holding
Promoters held 71.25 per cent stake in the company as of 31-Mar-2021, while FII and MF ownership in the firm stood at 11.37 per cent and 6.47 per cent, respectively.
Key Financials
The company reported consolidated sales of Rs 1976.0 crore for the quarter ended 31-Mar-2021, down 1.35 per cent from the previous quarter’s Rs 2003.0 crore and down 0.76 per cent from the year-ago quarter’s Rs 1961.0 crore. Its net profit for the latest quarter stood at Rs 324.0 crore, up 3.18 per cent from the same quarter a year ago.
